KN 93

reduces dopamine content in PC12h cells

Also Known As:

2-(N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl))amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; Benzenesulfonamide, N-(2-(((3-(4-chlorophenyl)-2-propenyl)methylamino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxy-; KN-93; KN93

Networked: 151 relevant articles (7 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tsokos, George C: 5 articles (07/2022 - 02/2011)
2.	Wang, Zaijie Jim: 5 articles (01/2020 - 04/2008)
3.	Koga, Tomohiro: 4 articles (07/2022 - 11/2014)
4.	Yoshida, Nobuya: 4 articles (07/2022 - 11/2014)
5.	Chen, Xiangyuan: 3 articles (11/2019 - 01/2017)
6.	Miao, Changhong: 3 articles (11/2019 - 01/2017)
7.	Wu, Qichao: 3 articles (11/2019 - 01/2017)
8.	Zhu, Minmin: 3 articles (11/2019 - 01/2017)
9.	Kranias, Evangelia G: 3 articles (01/2018 - 03/2007)
10.	Luo, Fang: 3 articles (01/2017 - 04/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "An acral melanoma cell line with high expression of TRPM1, CA11, was isolated from a patient to show the anti-tumor activity of KN93 in vitro and in vivo. " 09/01/2007 - "The in vivo administration of KN-93 to mice xenografted with human osteosarcoma cells significantly decreased intratibial and subcutaneous tumor growth. " 01/01/2020 - "Compared to free KN93, the MR52-KN93 hydrogel (MRK) improved the killing effects and levels of immunogenic cell death (ICD) on tumor cells significantly. " 07/21/2023 - "KN-93 significantly suppressed the tumor growth in mice xenografted with BAP1-deficient MMe cells. " 01/01/2020 - "Due to the dual role of KN93, the injection of the MRK hydrogel retarded the growth of subcutaneous melanoma tumors dramatically and resulted in a high number of mature dendritic cells of draining lymph nodes, significantly enhancing the portion of cytotoxic T cells and reduced number of M2-like tumor-associated macrophages (TAMs) in tumors. "
2.	Hypertrophy 12/01/2022 - "Moreover, RCAN1 depletion promoted mitochondrial translocation of CaMKII, which enhanced fission and septic hypertrophy, while inhibition of CaMKII with KN93 reduced excessive fission, improved LPS-mediated cardiac remodeling and dysfunction in RCAN1-/- mice. " 03/01/2023 - "A CaMKII inhibitor, KN-93 is able to enhance chondrogenesis of BM-MSCs and suppress chondrogenic hypertrophy, suggesting its potential applicability in cartilage tissue engineering." 03/01/2023 - "Ca2+/Calmodulin-dependent Protein Kinase II Inhibitor KN-93 Enhances Chondrogenesis of Bone Marrow Mesenchymal Stem Cells and Delays Chondrogenic Hypertrophy." 08/01/2010 - "3. Cardiomyocyte hypertrophy was inhibited by the CaMKII inhibitors KN93 and AIP and by overexpression of dominate negative CaMKIIdelta, but was potentiated by overexpression of wild-type CaMKIIdeltaB or CaMKIIdeltaC. " 02/01/2010 - "Specifically, systemic CaMKII inhibition with KN-93 prevented ANG II-mediated hypertension and medial hypertrophy in vivo. "
3.	Inflammation (Inflammations) 02/20/2022 - "KN93 can alleviate pancreatic injury and inflammation in SAP mice possibly through the ERK/MAPK signaling pathway." 01/01/2019 - "Overall, our findings suggest that KN-93 can effectively suppress oxidative stress and inflammation. " 01/01/2022 - "KN93 also reduced inflammation and improved the activation, proliferation and fibrosis of HSC. " 12/01/2020 - "KN-93, the CaMK4 inhibitor, reversed fetal resorption and excessive inflammation. " 01/01/2019 - "Increasing evidence has addressed the implication of KN-93 by blocking Ca2+ /calmodulin-dependent protein kinase II (CaMKII), suppressing oxidative stress and inflammation, and also reducing neuron decay. "
4.	Dyskinesias (Dyskinesia) 11/01/2018 - "Disrupt of this link by intrastriatal infusion of KN-93 or MK-801 ameliorated dyskinesia in 6-OHDA-lesioned PD rats." 01/01/2013 - "Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease."
5.	Fibrosis (Cirrhosis) 01/01/2022 - "KN93 also reduced inflammation and improved the activation, proliferation and fibrosis of HSC. " 10/28/2023 - "Pretreatment with KN-93 (a CaMKII inhibitor) blocked GF-induced Stat3 activation and significantly suppressed myocardial fibrosis. "

Related Drugs and Biologics

1.	Calcium-Calmodulin-Dependent Protein Kinase Type 2
2.	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)
3.	protein kinase modulator
4.	Levodopa (L Dopa)
5.	Mitogen-Activated Protein Kinase Kinases (MEKs)
6.	Hydrogels
7.	Brain-Derived Neurotrophic Factor (BDNF)
8.	zeta-inhibitory peptide
9.	U 0126 (UO 126)
10.	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one

Related Therapies and Procedures

1.	Injections
2.	Spinal Injections
3.	Stents
4.	Therapeutics
5.	Ligation